Compare Stocks: CBIO, NKTR, AMLX, and BCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$21.43 -0.9%	$18.28	$7.63 ▼ $24.60	$2.39B	-0.21	1.41 million shs	1.01 million shs
BCRX BioCryst Pharmaceuticals	$9.94 +2.1%	$9.50	$6.00 ▼ $11.22	$2.54B	0.55	4.95 million shs	2.12 million shs
CBIO Crescent Biopharma	$17.48 +2.0%	$16.77	$8.72 ▼ $27.41	$649.21M	1.23	273,173 shs	126,111 shs
NKTR Nektar Therapeutics	$72.67 -0.5%	$67.98	$25.34 ▼ $109.00	$2.46B	1.14	1.04 million shs	681,790 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	-5.21%	+21.86%	+68.20%	+170.38%
BCRX BioCryst Pharmaceuticals	0.00%	+3.84%	+4.84%	+8.58%	+16.37%
CBIO Crescent Biopharma	0.00%	+1.78%	+16.20%	-7.60%	+24.29%
NKTR Nektar Therapeutics	0.00%	-4.52%	+6.97%	+6.71%	+167.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$21.43 -0.9%	$18.28	$7.63 ▼ $24.60	$2.39B	-0.21	1.41 million shs	1.01 million shs
BCRX BioCryst Pharmaceuticals	$9.94 +2.1%	$9.50	$6.00 ▼ $11.22	$2.54B	0.55	4.95 million shs	2.12 million shs
CBIO Crescent Biopharma	$17.48 +2.0%	$16.77	$8.72 ▼ $27.41	$649.21M	1.23	273,173 shs	126,111 shs
NKTR Nektar Therapeutics	$72.67 -0.5%	$67.98	$25.34 ▼ $109.00	$2.46B	1.14	1.04 million shs	681,790 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	-5.21%	+21.86%	+68.20%	+170.38%
BCRX BioCryst Pharmaceuticals	0.00%	+3.84%	+4.84%	+8.58%	+16.37%
CBIO Crescent Biopharma	0.00%	+1.78%	+16.20%	-7.60%	+24.29%
NKTR Nektar Therapeutics	0.00%	-4.52%	+6.97%	+6.71%	+167.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	2.90	Moderate Buy	$26.13	21.91% Upside
BCRX BioCryst Pharmaceuticals	2.67	Moderate Buy	$20.60	107.24% Upside
CBIO Crescent Biopharma	2.60	Moderate Buy	$29.40	68.19% Upside
NKTR Nektar Therapeutics	2.75	Moderate Buy	$150.00	106.41% Upside

Current Analyst Ratings Breakdown

Latest CBIO, NKTR, AMLX, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $30.00
8/7/2026	CBIO Crescent Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
8/6/2026	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$21.00 ➝ $20.00
8/5/2026	AMLX Amylyx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $26.00
7/22/2026	NKTR Nektar Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$153.00
7/20/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $24.00
7/16/2026	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/13/2026	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$12.00
7/7/2026	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	27.33	N/A	N/A	$2.78 per share	7.71
BCRX BioCryst Pharmaceuticals	$940.61M	2.70	$1.26 per share	7.87	($0.57) per share	-17.44
CBIO Crescent Biopharma	$10.84M	59.89	N/A	N/A	$14.32 per share	1.22
NKTR Nektar Therapeutics	$55.23M	44.46	N/A	N/A	$4.41 per share	16.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	13.81	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)

Latest CBIO, NKTR, AMLX, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
CBIO Crescent Biopharma	N/A	9.66	9.66
NKTR Nektar Therapeutics	N/A	10.42	10.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
BCRX BioCryst Pharmaceuticals	85.88%
CBIO Crescent Biopharma	75.19%
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
BCRX BioCryst Pharmaceuticals	3.80%
CBIO Crescent Biopharma	24.84%
NKTR Nektar Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	111.42 million	99.28 million	Optionable
BCRX BioCryst Pharmaceuticals	530	255.54 million	245.83 million	Optionable
CBIO Crescent Biopharma	50	37.14 million	27.92 million	No Data
NKTR Nektar Therapeutics	220	33.79 million	32.94 million	Optionable

CBIO, NKTR, AMLX, and BCRX Headlines

Recent News About These Companies

Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway

August 17 at 6:30 AM | tipranks.com

Nektar Therapeutics (NASDAQ:NKTR) Receives $150.00 Average PT from Analysts

August 17 at 3:44 AM | americanbankingnews.com

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise

August 15 at 2:16 AM | finance.yahoo.com

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

August 14 at 9:16 PM | finance.yahoo.com

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming

August 14 at 3:00 PM | seekingalpha.com

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

August 14 at 12:05 PM | zacks.com

Nektar Therapeutics (NKTR) Q2 2026

August 14 at 11:15 AM | 247wallst.com

Nektar: Q2 Earnings Snapshot

August 14 at 6:14 AM | chron.com

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Nektar Therapeutics Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

August 13, 2026 | zacks.com

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

August 13, 2026 | marketbeat.com

Nektar Reports $40.6 Million Second-Quarter Loss as Revenue Reaches $10.1 Million

August 13, 2026 | quiverquant.comQ

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Brokerages

August 12, 2026 | marketbeat.com

California State Teachers Retirement System Grows Stock Position in Nektar Therapeutics $NKTR

August 12, 2026 | marketbeat.com

Nektar Therapeutics (NKTR) Projected to Post Earnings on Thursday

August 12, 2026 | americanbankingnews.com

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

August 11, 2026 | prnewswire.com

Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday

August 11, 2026 | defenseworld.netD

Nektar Therapeutics $NKTR Shares Sold by Renaissance Technologies LLC

August 9, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Takes $1.14 Million Position in Nektar Therapeutics $NKTR

August 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, NKTR, AMLX, and BCRX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$21.43 -0.20 (-0.92%)

As of 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.94 +0.20 (+2.05%)

As of 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Crescent Biopharma NASDAQ:CBIO

$17.48 +0.34 (+1.98%)

As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Nektar Therapeutics NASDAQ:NKTR

$72.67 -0.35 (-0.48%)

As of 04:00 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBIO, NKTR, AMLX, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBIO, NKTR, AMLX, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBIO, NKTR, AMLX, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, NKTR, AMLX, and BCRX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioCryst Pharmaceuticals NASDAQ:BCRX

Crescent Biopharma NASDAQ:CBIO

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBIO, NKTR, AMLX, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBIO, NKTR, AMLX, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBIO, NKTR, AMLX, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, NKTR, AMLX, and BCRX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

BioCryst Pharmaceuticals NASDAQ:BCRX

Crescent Biopharma NASDAQ:CBIO

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools